COVID-19 severity and corticosteroid treatment have minimal effect on specific antibody production.

Publication date: Oct 24, 2024

Dexamethasone is currently administered for Coronavirus disease 2019(COVID-19); however, there are concerns about its effect on specific antibodies’ production. The aim of this study was to evaluate whether specific antibodies were affected by COVID-19 severity and corticosteroid treatment. Of 251 confirmed COVID-19 patients admitted to our hospital between January 26 and August 10, 2020, the early period of the pandemic, 75 patients with sera within 1 month of onset and 1 month or longer were included in the research. A total of 253 serum samples from these patients were collected. The levels of specific antibodies for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), immunoglobulin G (IgG) and M (IgM), were measured retrospectively. The results were compared separately of each COVID-19 severity, and with or without corticosteroid treatment. Among the 75 patients, 47, 18, and 10 had mild, moderate, and severe disease, respectively. The median age was 53. 0 years and 22 (29%) were women. The most common comorbidities were hypertension and dyslipidemia. Corticosteroids were administered to 20 (27%) and 10 (53%), patients with moderate and severe disease, respectively. The positivity rates IgM increased first, and IgG was almost always positive after day 16, regardless of the severity of COVID-19. On days 6-10, both IgG and IgM positivity rates were higher in patients with moderate disease than in those with mild or severe disease. In patients with moderate disease, IgG positivity was similar over time, regardless of corticosteroid treatment. In COVID-19 patients, specific IgG is positive and maintained for a long period of time, even after corticosteroid treatment. The effect of corticosteroid treatment in a COVID-19 epidemiological study using specific IgG antibodies was considered minor. COVID-19 patients were more likely to receive oxygen if IgM was positive 1 week after onset, but not mechanical ventilation. IgM measurement 1 week after onset may predict COVID-19 severity.

Open Access PDF

Concepts Keywords
2019covid Adrenal Cortex Hormones
Antibodies Adrenal Cortex Hormones
Coronavirus Adult
Dyslipidemia Aged
Mild Antibodies, Viral
Antibodies, Viral
Antibody Formation
Corticosteroids
COVID-19
COVID-19
COVID-19 Drug Treatment
Dexamethasone
Dexamethasone
Female
Humans
Immunoglobulin G
Immunoglobulin G
Immunoglobulin M
Immunoglobulin M
Male
Middle Aged
Retrospective Studies
SARS-CoV-2
Severity
Specific antibody

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Dexamethasone
disease IDO production
disease MESH hypertension
disease MESH dyslipidemia
drug DRUGBANK Oxygen
disease MESH Long Covid
disease MESH Infectious Diseases
pathway REACTOME Reproduction
drug DRUGBANK Esomeprazole
drug DRUGBANK Gold
disease MESH syndrome
disease MESH infection
disease MESH re infection
drug DRUGBANK Ademetionine
drug DRUGBANK Etoperidone
disease IDO symptom
disease IDO assay
disease IDO protein
disease MESH Emergency
disease MESH complications
disease MESH pneumonia
disease MESH diabetes mellitus
disease MESH COPD
disease MESH ESRD
disease IDO immunodeficiency
disease MESH acute respiratory distress syndrome
disease IDO immunosuppression
disease MESH Malignancy
drug DRUGBANK Favipiravir
drug DRUGBANK Lopinavir
drug DRUGBANK Ritonavir
drug DRUGBANK Tocilizumab
disease MESH Death
drug DRUGBANK Hydrocortisone
drug DRUGBANK Methylprednisolone
disease MESH tics
drug DRUGBANK Coenzyme M
disease MESH obesity
disease IDO reagent
drug DRUGBANK Isoxaflutole
disease MESH AIDS
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH coronavirus infections
disease MESH severe acute respiratory syndrome
disease MESH viral load
disease MESH Allergy
drug DRUGBANK Flunarizine
disease IDO cell

Original Article

(Visited 1 times, 1 visits today)